308.44
+15.03(+5.12%)
Currency In USD
| Previous Close | 293.41 |
| Open | 294 |
| Day High | 312.52 |
| Day Low | 293 |
| 52-Week High | 368.29 |
| 52-Week Low | 168.25 |
| Volume | 682,034 |
| Average Volume | 420,309 |
| Market Cap | 6.73B |
| PE | -12.32 |
| EPS | -25.03 |
| Moving Average 50 Days | 286.92 |
| Moving Average 200 Days | 256.7 |
| Change | 15.03 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $3,216.27 as of December 21, 2024 at a share price of $308.44. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $3,325.14 as of December 21, 2024 at a share price of $308.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 06, 2024 1:00 PM GMT
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wedn
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire Inc.
Oct 31, 2024 11:00 AM GMT
Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
GlobeNewswire Inc.
Oct 30, 2024 12:00 PM GMT
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatoh